NCT07252570Completed
Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
Introduction: Pre-hepatic portal hypertension of malignant origin can lead to severe complications such as refractory ascites or gastrointestinal bleeding, significantly impairing patients' quality of life. Available therapeutic options are mainly symptomatic and do not address the venous obstruction. Portal vein stenting represents a minimally invasive alternative, which remains poorly studied in this setting. The aim of our study was to evaluate portal stent patency, as well as clinical efficacy and safety, in patients with symptomatic malignant stenosis or occlusion of the portal system. Methods: The team conducted a retrospective cohort study including 63 consecutive patients treated between April 2004 and March 2024 at CHU l'Archet and CAL Nice for symptomatic malignant stenosis or occlusion of the portal system. All patients underwent percutaneous transhepatic portal vein stenting with uncovered self-expandable metallic stents. The primary endpoint was stent patency, defined as the interval between implantation and the occurrence of an occlusion confirmed by imaging or end of follow-up. Secondary endpoints included technical success, clinical success (improvement of portal hypertension signs), and the occurrence of adverse events, graded according to the 2017 SIR classification.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 63 (actual)
- First submitted
- 8 Sept 2025
- Start date
- 8 Apr 2004
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- High blood pressure, Pancreatic cancer
- NCT number
- NCT07252570
What you commit to
- Study type: Observational
- Participants enrolled: 63
- From 8 Apr 2004 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Obstruction or stenosis secondary to a malignant/neoplastic process.
Who the study is looking for
- Age ≥ 18 years.
- Presence of symptoms related to portal hypertension (e.g., refractory ascites, gastrointestinal bleeding).
- Imaging evidence of stenosis or obstruction of the portal venous system (main portal vein, superior and/or inferior mesenteric vein, spleno-mesenteric confluence, and/or splenic vein).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nice Coordinator of this site? Confirm its status | Nice | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.